<DOC>
	<DOCNO>NCT02684136</DOCNO>
	<brief_summary>This study compare sleep , pain daytime sleepiness/fatigue people insomnia co-morbid fibromyalgia treat short-term suvorexant 20 mg versus placebo .</brief_summary>
	<brief_title>Suvorexant Insomnia Co-morbid With Fibromyalgia</brief_title>
	<detailed_description>It become clear relation sleep pain bidirectional ; acute chronic pain associate disturbed sleep disturbed sleep enhances pain . Experimental study show reduced fragmented sleep pain-free normal increase pain sensitivity daily self-report study chronic pain patient show poor night sleep follow enhanced next-day pain . In mediation analysis large clinical data set find sleep-pain side bidirectional relation , oppose pain-sleep side , account great variance . These data would suggest improve sleep chronic pain disorder attenuate daytime pain . Most drug use treat chronic pain facilitate inhibitory central nervous system mechanisms primary mechanism action . Suvorexant , recently approve FDA treatment insomnia characterize difficulty sleep onset sleep maintenance , unique mechanism action . Suvorexant selective antagonist orexin receptor ( OX1R OX2R ) . Orexins consider involved arousal maintenance wake state . As , suvorexant may provide unique clinical benefit treatment chronic pain condition co-morbid insomnia , specifically fibromyalgia putative central hyperarousal hypersensitization . Thus , project proposes study objective clinical measure sleep , pain , daytime sleepiness fatigue patient fibromyalgia co-morbid insomnia treat short-term suvorexant 20 mg versus placebo . Those qualify receive suvorexant 20 mg placebo 9 night cross design 7 night washout treatment . Overnight sleep recording ( PSGs ) collect night 7 8 crossover treatment arm determine objective sleep measure . During day follow night 7 arm , Multiple Sleep Latency Test ( MSLT ) 1000 , 1200 , 1400 , 1600 hr conduct nociceptive sensitivity [ finger withdrawal latency ( FWL ) ] test radiant heat stimulus ( 1100 1500 hr ) conduct day 1 day 8 . Self-reported mood pain index also complete prior FWL test . Primary outcome measure include PSG sleep efficacy FWL response condition ( suvorexant 20 mg versus placebo ) .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>meet Diagnostic Statistical Manual 5th ed criterion insomnia meet American College Rheumatology criterion fibromyalgia otherwise good psychiatric stable physical health primary sleep disorder pain symptom unrelated fibromyalgia current pregnancy breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>insomnia</keyword>
	<keyword>fibromyalgia</keyword>
	<keyword>polysomnography</keyword>
	<keyword>pain management</keyword>
</DOC>